Antimotility代理慢性腹泻与艾滋病毒/艾滋病人。

文章的细节

引用

复制到剪贴板

Nwachukwu CE, Okebe居

Antimotility代理慢性腹泻与艾滋病毒/艾滋病人。

科克伦数据库系统启2008 10月8;(4):CD005644。cd005644.pub2 doi: 10.1002/14651858.。

PubMed ID

18843696 (在PubMed

]

文摘

背景:艾滋病腹泻发病率和死亡率的常见原因是HIV阳性个体,特别是在撒哈拉以南非洲,70%的人死于艾滋病的发生。它经常妥协的生活质量都在那些接受抗逆转录病毒治疗(ART)和艺术天真。实证antidiarrhoeal治疗可能需要在大约50%的情况下(或特发性的情况下造成的抗逆转录病毒治疗。beplayappAntimotility代理(洛派丁胺、苯乙哌啶、可待因)和吸附剂(水杨酸亚铋,高岭土/果胶,凹凸棒石)是现成的,和被发现是有用的在这种情况下,通常使用。Antimotilitics阿片类药物,减少粪便输出通过减少肠道活动从而增加粪便在肠道运输时间,促进液体和电解质保留在吸附剂法通过绑定到液体,毒素和其他物质来改善粪便一致性和消除毒素。由于其管理的潜在影响慢性腹泻与艾滋病毒/艾滋病人,我们回顾了antimotility代理控制慢性腹泻的有效性在免疫功能不全的州由艾滋病毒/艾滋病引起的。目的:评估的有效性antimotility代理在控制慢性腹泻与艾滋病毒/艾滋病人。搜索策略:我们搜查了Medline和EMBASE, Cochrane对照试验注册,Cochrane艾滋病毒/艾滋病的2006年11月注册和AIDSearch数据库。我们也联系了他们,疾控中心,制药公司和该领域的专家信息以前或正在进行的试验和检查参考列表检索研究,无论语言出版的地位。选择标准:随机对照试验比较antimotility剂或吸附剂与另一个antimotility代理,安慰剂,一种吸附剂或没有治疗儿童和成人患有艾滋病毒和出现腹泻持续时间三个或更多的星期。 DATA COLLECTION AND ANALYSIS: Two authors independently undertook study selection and examined full articles of potentially eligible studies. MAIN RESULTS: One trial was found assessing the use of an adsorbent (attapulgite) compared to a placebo for chronic diarrhoea in people with HIV/AIDS. It included 91 adults (Aged 18 to 60), diagnosed with AIDS and experiencing diarrhoea for at least 7 days. There was no evidence that attapulgite is superior to placebo in controlling diarrhoea by reducing stool frequency and normalising stool consistency on days 1 (0.34 (95% CI 0.01 - 8.15)), 3 (1.35 (95% CI 0.51 - 3.62)) and 5 (1.74 (95% CI 0.89 - 3.38)). This was a small trial and may not have had enough power to show evidence of effects. Five deaths were reported which was not classified according to the arms of the study.Studies assessing the use of antimotility agents were not found. AUTHORS' CONCLUSIONS: This review highlights the absence of evidence for the use of antimotility agents and adsorbents in controlling diarrhoea in people with HIV/AIDS. While no trials assessing the use of Antimotilitics were found, the retrieved study showed that attapulgite was not better than placebo in controlling diarrhoea in HIV/AIDS patients . For optimum patient care, these agents can still be used, with greater emphasis placed on adjunct therapies like massive fluid replacement while evidence for practice is awaited from further studies and reviews.

beplay体育安全吗DrugBank数据引用了这篇文章

药物

凹凸棒石